Boehringer Ingelheim R&D
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 16, 2024 06:05 ET | Boehringer Ingelheim
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52...
Le PIONeeR Project p
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024
September 12, 2024 04:21 ET | The PIONeeR Project
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter...
logoPioneer plein.png
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024
September 12, 2024 04:21 ET | The PIONeeR Project
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024 The Presidential Symposium "Eyes to the future" will feature the first-ever...
Cylinder Logo.png
Study Finds Cylinder Digital Health Platform Significantly Improves Digestive Health Symptoms
September 10, 2024 10:00 ET | Cylinder
Study Finds Cylinder Digital Health Platform Significantly Improves Digestive Health Symptoms
pharmather logo.png
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
August 19, 2024 08:00 ET | PharmaTher Holdings Ltd.
TORONTO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
Eclipse Logo.png
Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema (DME)
August 12, 2024 07:45 ET | Eclipse Life Sciences
RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies...
MycoThrive™ Lion's Mane by AFS
AFS Introduces MycoThrive™ Lion's Mane: A Clinically Studied Ingredient for Cognitive Performance
July 13, 2024 12:55 ET | Applied Food Sciences, Inc.
Kerrville, Texas, July 13, 2024 (GLOBE NEWSWIRE) -- Applied Food Sciences (AFS) is proud to announce the launch of MycoThrive™ Lion's Mane, a groundbreaking functional ingredient recently clinically...
Crossject met en per
Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.
June 26, 2024 01:30 ET | CROSSJECT
L'étude de référence RAMPART a établi l'injection intramusculaire (IM) de midazolam comme le standard pour la gestion d’urgence préhospitalière des crises d'épilepsie par rapport à l'injection...
Crossject elaborates
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
June 26, 2024 01:30 ET | CROSSJECT
Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine...
revive-therapeutics.png
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
June 12, 2024 09:05 ET | Revive Therapeutics Ltd.
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...